P22D

Overview

P22D is a BCR-ABL PROTAC degrader based on Dasatinib ( HY-10181 ), with a DC 50 value of approximately 10 nM for the wild-type BCR-ABL protein. P22D cannot degrade the BCR-ABL T315I mutant. P22D has inhibitory activity against K562 cells (wild type), but is ineffective against BaF3-BCR-ABL (T315I) cells. P22D can be used for research on chronic myeloid leukemia and acute lymphocytic leukemia. (Pink: Bcr-Abl ligand ( HY-107447 ); Blue: Cereblon ligand ( HY-14658 ); Black: linker ( HY-180980 )).

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > Bcr-Abl

Product Information

• Catalog No.: HY-180979
• CAS No.: 2635386-51-3
• Molecular Formula: C49H58ClN13O10S
• Molecular Weight: 1056.58
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source